Milestone payment for sustained-delivery device
January 25th 2012Genentech announced it will make its first milestone payment to ForSight VISION4 Inc. as part of an exclusive license agreement to develop an investigational device designed to provide sustained delivery of the vascular endothelial growth factor inhibitor ranibizumab (Lucentis).
WFO, WFG myopic PRK clinical outcomes compared
January 25th 2012Results from a prospective randomized eye-to-eye study comparing wavefront-optimized (WFO) and wavefront-guided (WFG) myopic PRK show the WFO technique affords faster visual recovery, but ultimately, quantity and quality of vision appear to be better after WFG PRK, said co-investigators Anthony C. Liu, MD, and Edward Manche, MD.
Structural data may signal glaucoma
January 15th 2012Analyses of data from baseline structural imaging studies performed in two large prospective, observational glaucoma cohort trials suggest inter-eye asymmetry in optic disc topography parameters and average retinal nerve fiber layer thickness may provide an additional tool to identify eyes with early signs of glaucoma.
Process of aqueous outflow uses unifying concept
January 15th 2012A new paradigm of aqueous outflow positing that it is a dynamic, pump-like process regulated through pulsatile mechanisms provides a conceptual framework unifying structure and function throughout the entire trabecular meshwork in both health and disease.
Hageman receives Lighthouse Award
January 11th 2012Gregory Hageman, PhD, has been selected for the 2011 Lighthouse International Pisart Vision Award. Presented annually, this award honors an individual who has “distinguished himself or herself by invention or otherwise in the prevention, cure, treatment, or care of blindness.”
Interim results favorable for QPI-1007
January 11th 2012Quark Pharmaceuticals Inc. has announced favorable interim results from the first two cohorts of its open-label, first-in-human phase I clinical study of QPI-1007, its proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy.
Daily aspirin linked to AMD risk
January 11th 2012Data from a large European study link daily aspirin use to increased risk of age-related macular degeneration (AMD). Researchers found that people aged 65 and older who took aspirin daily had double the risk of developing wet AMD, compared with those who took it less frequently.
EGP-437 phase III study begins
January 11th 2012EyeGate Pharma has enrolled the first patient in a milestone phase III pivotal study of its lead product EGP-437 (a late-stage asset with multiple indications for inflammatory ocular indications) for the treatment of anterior uveitis. The company, a private specialty pharmaceutical company developing therapeutics designed to address patient compliance and patient throughput, enrolled the patient at Tauber Eye Center in Kansas City, MO.
Evaluation helps presbyopia-correcting IOL complaints
January 11th 2012An algorithmic approach to problem solving for patients who are dissatisfied after implantation of presbyopia-correcting IOLs aims to streamline identification of the etiology of the visual complaints and implementation of a successful solution, said Parag Majmudar, MD.
Deep anterior lamellar keratoplasty meets penetrating keratoplasty
January 1st 2012Results from the prospective, multicenter, randomized, controlled Dutch Lamellar Corneal Transplantation Study support performing deep anterior lamellar keratoplasty instead of penetrating keratoplasty in eyes needing corneal transplantation for stromal pathology not affecting the endothelium.